US · Healthcare · Biotechnology
EPS came in at 0.07 against a street estimate of 0.14 — a miss of 50.0%.
with an average price target of $17.67.
| Fund | Stake |
|---|---|
| Madison Avenue Partners, LP | 17.74% |
| Weiss Asset Management LP | 14.36% |
| BlackRock Inc | 8.79% |
| Newtyn Management LLC | 6.61% |
| Irenic Capital Management LP | 5.32% |
| Vanguard Capital Management, LLC | 3.41% |
| State Street Corp | 2.56% |
| Two Sigma Investments LLC | 2.36% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 THERAVANCE BIOPHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Merger completion date: September 23, 2026 • Cash consideration per share: $17.00 • | 2026-09-23 |
| Shareholder vote results · Q3 2026 THERAVANCE BIOPHARMA, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Shareholder vote held: September 18, 2026 for proposed merger with Zymeworks Inc. • | 2026-09-18 |
| Company announcement · Q3 2026 THERAVANCE BIOPHARMA, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Agreement Date: June 28, 2026 with Zymeworks Inc. • Shareholder Vote: Schedu | 2026-09-10 |
| Company announcement · Q3 2026 THERAVANCE BIOPHARMA, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company presented Phase 3 CYPRESS Study (0197) results on August 25, 2 | 2026-08-25 |
| Quarterly report · Q2 2026 THERAVANCE BIOPHARMA, INC. — Q2 2026 SUMMARY HEADLINE NUMBERS • Cash & equivalents: $219.8 million (June 30, 2026) vs. $167.8 million (Dec 31, 2025) | 2026-08-11 |
| Results announced · Q3 2026 THERAVANCE BIOPHARMA Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Acquisition Deal: Zymeworks to acquire company for $17.00 per share in cash, plus | 2026-08-10 |
| Material agreement · Q2 2026 THERAVANCE BIOPHARMA MERGER SUMMARY HEADLINE NUMBERS • Acquisition price: $17.00 per share in cash (plus contingent value rights) • Acquirer: Zymewo | 2026-06-29 |
| Board / officer change · Q2 2026 THERAVANCE BIOPHARMA, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Senior Vice President Áine Miller's employment termination scheduled for November 15 | 2026-06-23 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Theravance Biopharma Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.